A PHASE 3, RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT SC WITH STANDARD TREATMENT COMPARED TO STANDARD TREATMENT ALONE IN IMPROVING DISEASE ACTIVITY IN ADULTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHY (IIM)

Registry ID

IM101-611

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

BRISTOL-MYERS SQUIBB CANADA

Start date

2021-09-13

Completion date

2021-02-26

Last update

2019-01-30

Conditions

• IDIOPATHIC INFLAMMATORY MYOPATHY

Related clinical trials

• A PHASE 3, SINGLE-ARM, MULTICENTER, OPEN-LABEL EXTENSION OF STUDY ARGX-113-2007 TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD PH20 SC IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHY

View on source registry